Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 6101–6150 of 18646
On March 14, 2024, the Registrant and Mr. Berg agreed that such resignations will take effect on March 20, 2024.
the Board appointed Kenneth Mushinski as the President and Chief Executive Officer of the Registrant, and as a director of the Registrant, in each case effective as of May 1, 2024.
appointed Alan Ellingson, the Company's Senior Vice President, Finance and Analytics, as the Company's Chief Financial Officer, principal financial officer and principal accounting officer, effective as of May 1, 2024
the Company announced the appointment of Tim Zimmer as the Company’s Chief Executive Officer, effective March 15, 2024.
Mr. Zimmer succeeds Gerard Law, who departed the Company as its Chief Executive Officer, effective March 15, 2024, following notice received that same day.
On March 12, 2024, the board of directors (the “ Board ”) of QT Imaging Holdings, Inc. (the “ Company ”) terminated Dr. John C. Klock from his position as Chief Executive Officer effective as of March 12, 2024.
On March 12, 2024, the Board appointed Dr. Raluca Dinu, who is also a member of the Board, to be employed as its Acting Chief Executive Officer effective as of March 12, 2024.
On February 15, 2024, the board of directors (the “Board”) of Avangrid, Inc. (the “Corporation”), upon the recommendation of its compensation and nominating committee of the Board (the “Compensation and Nominating Committee”), promoted Justin Lagasse to the position of Senior Vice President – Chief Financial Officer and Controller of the Corporation.
the Board appointed Cris Keirn, the Company’s Interim Chief Executive Officer and principal executive officer, to serve as the Company’s Chief Executive Officer and as a director on the Board
On March 14, 2024, Healthcare Triangle, Inc., a Delaware corporation (the “ Company ”), appointed Mr. Anand Kumar, as interim chief executive officer of the Company (the “ Interim CEO ”), effective March 15, 2024
Accordingly, the CEO Agreement expires by its terms on May 26, 2024 (the “ Expiration Date ”) and Mr. O’Brien’s employment as Chief Executive Officer of the Company will terminate as of the Expiration Date.
the Board of Directors (the “Board”) of DallasNews Corporation (the “Company”) appointed Cathy Collins as the Company’s Chief Financial Officer
Ms. Collins succeeds Mary Kathryn Murray, who has served as the Company’s Chief Financial Officer since April 2015. Ms. Murray will continue to serve as President
On March 18, 2024, the board of directors of the Company, appointed Claudio Flamini as Chief Financial Officer of the Company.
The company wishes to thank Rachel Boulds for her hard work and dedication in this role.
the Board appointed Paul Vassilakos as Executive Chairman and Chief Executive Officer of the Company, effective immediately
On March 17, 2024, Kevin O’Donnell resigned as Executive Chairman and Interim Chief Executive Officer of the Company, effective immediately.
Under the Addendum, effective as of March 15, 2024, Mr. Hernon shall resign without Good Reason (as defined in the Hernon Employment Agreement) as the Chief Financial Officer of the Company, and shall instead provide consulting services to the Company pursuant to the terms of the Hernon Consulting Agreement.
In connection with Mr. Hernon’s transition to a consulting role, effective as of March 15, 2024, the Company appointed Leah Lunger as its Interim Chief Financial Officer, interim principal financial officer and interim principal accounting officer.
The board of directors (the “Board”) of Chromocell Therapeutics Corporation (the “Company”) has appointed Francis Knuettel II as Chief Executive Officer of the Company, effective March 13, 2024.
On March 18, 2024, the Company announced that Sean Blitchok will resign upon mutual agreement with the Board as the Company’s Treasurer and Chief Financial Officer, including as principal accounting officer and principal financial officer, effective as of April 1, 2024.
On March 18, 2024, the Company announced that the Board has appointed Laurence E. Katz, age 54, as the Company’s Chief Financial Officer and class I director of the Board, effective upon the commencement of his employment, which is expected to be April 1, 2024.
On March 13, 2024, the Board of Directors of Cognex Corporation (the "Company") designated Laura MacDonald, Vice President of Finance, as the Company's principal financial officer and principal accounting officer on an interim basis, effective March 15, 2024.
On January 3, 2024, the Company announced Mr. Todgham's resignation, effective March 15, 2024
Following the departure of Michael J. DeVito as Freddie Mac’s Chief Executive Officer (CEO) effective March 15, 2024
President Michael T. Hutchins has been appointed to the additional role of interim CEO of the company effective March 16, 2024 and will become a member of Freddie Mac’s Board of Directors on that date.
On March 12, 2024, the Company and Mr. Mauch entered into an amended and restated employment agreement (the “Mauch Employment Agreement”), effective as of the Effective Date.
On March 15, 2024, Gamer Pakistan Inc. (the “Company”) appointed Jerry J. Goldstein as its interim Chief Financial Officer while it conducts a search for a permanent Chief Financial Officer.
The Company’s prior Chief Financial Officer, Mr. Hemant Jain, had died unexpectedly.
the Board elected Brian Windsor, Ph.D., as the Chief Executive Officer of the Company and a member of the Board, effective as of March 11, 2024
Manuel C. Alves-Aivado, M.D., Ph.D., agreed that his employment with the Company would cease and he would resign from his position as Chief Executive Officer of the Company, effective as of March 11, 2024
On March 14, 2024, Frank Karbe resigned from his position as CEO, President, Treasurer and Secretary.
On March 14, 2024, the Board appointed Craig R. Jalbert, age 61, as the Company’s CEO, President, Treasurer, Secretary, and sole member of the Board.
John Butler, the Company’s President and Chief Executive Officer, will act as interim principal financial officer from the Transition Date.
On March 15, 2024, Akebia Therapeutics, Inc. (the “Company”) and Ellen Snow mutually agreed that she would transition from her role as the Company’s Senior Vice President, Chief Financial Officer and Treasurer, effective March 22, 2024 (the “Transition Date”).
the following individuals were appointed to serve as executive officers of the Company: Name Position Tie (James) Li Chief Executive Officer Zhiyi (Jonathan) Zhang President George Yutuc Chief Financial Officer Darin Carpenter Chief Operating Officer Varto Doudakian Vice President
the following individuals were appointed to serve as executive officers of the Company: Name Position Tie (James) Li Chief Executive Officer Zhiyi (Jonathan) Zhang President George Yutuc Chief Financial Officer Darin Carpenter Chief Operating Officer Varto Doudakian Vice President
Mr. Nadir Ali and Ms. Wendy Loundermon resigned as Chief Executive Officer and Chief Financial Officer of the Company, respectively.
the board of directors of the Company (the "Board") appointed Mr. Scott Pomeroy as Chief Executive Officer of the Company and Ms. Brooke Martellaro as Chief Financial Officer of the Company.
Mr. Nadir Ali and Ms. Wendy Loundermon resigned as Chief Executive Officer and Chief Financial Officer of the Company, respectively.
the board of directors of the Company (the "Board") appointed Mr. Scott Pomeroy as Chief Executive Officer of the Company and Ms. Brooke Martellaro as Chief Financial Officer of the Company.
Effective March 14, 2024, Nelson Cabatuan, age 46, has been appointed to the position of Chief Financial Officer of Lexaria Bioscience Corp.
On March 13, 2024, Meng-Lin Sung, the Chief Financial Officer of Ainos, Inc. (the “Company”), resigned from her positions with the Company, effective as of such date.
As of the Effective Date, Joseph Jordan, the Company’s Chief Financial Officer, will serve as the Company’s principal financial officer and principal accounting officer.
the Board announced the appointment of Mr. Sanjay Chowbey to serve as Kennametal’s President and Chief Executive Officer starting on June 1, 2024.
On the Effective Date, the Debtors’ officers, including Mr. Gareth T. Joyce, Chief Executive Officer and President of the Company, and Mr. Justin Derek Pugh, Acting Chief Financial Officer of the Company, were replaced pursuant to the Plan by the Reorganized Debtors’ new officers, each effective as of March 13, 2024.
On the Effective Date, the Debtors’ officers, including Mr. Gareth T. Joyce, Chief Executive Officer and President of the Company, and Mr. Justin Derek Pugh, Acting Chief Financial Officer of the Company, were replaced pursuant to the Plan by the Reorganized Debtors’ new officers, each effective as of March 13, 2024.
the Company appointed Adam Miller as the Company’s Chief Executive Officer and Andrew Hess as the Company’s Chief Financial Officer, both effective February 26, 2024.
the Company appointed Adam Miller as the Company’s Chief Executive Officer and Andrew Hess as the Company’s Chief Financial Officer, both effective February 26, 2024.
David A. Jackson stepped down as Chief Executive Officer of the Company and as a member of the Board.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.